您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Ketorolac hemicalcium
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ketorolac hemicalcium
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:167105-81-9
包装与价格:
包装价格(元)
5 mg电议
50 mg电议
100 mg电议

产品介绍
Ketorolac (RS37619) hemicalcium 是一种非甾体抗炎剂,为非选择性的COX抑制剂,对 COX-1 和 COX-2 的IC50值分别为 20 nM 和 120 nM。Ketorolac tromethamine 被用作 0.5% 滴眼液,用于过敏性结膜炎、黄斑囊状水肿、术中瞳孔缩小、术后眼炎疼痛的研究。Ketorolac hemicalcium 也是一种 DDX3 抑制剂,可用于癌症的研究。

产品描述

Ketorolac (RS37619) hemicalcium is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC 50 s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorola chemicalcium is also a DDX3 inhibitor that can be used for cancer research [1] [4].

体外活性

Ketorolac (RS37619) salt (0-30 μM, 48 h) effectively kills the oral cancer cells [4]. Ketorolac salt (0-5 μM, 48 h) inhibits the expression of DDX3 protein, and induces apoptosis in H357 cells [4]. Ketorolac salt (0-2.5 μM, 0-16 h) inhibits the proliferation of oral cancer cells [4]. Ketorolac salt (0-50 μM) directly interacts with DDX3 and inhibits the ATPase activity [4]. Cell Viability Assay [4] Cell Line: HOK, SCC4, SCC9 and H357 cells Concentration: 0-30 μM Incubation Time: 48 h Result: Showed inhibition with IC 50 s of 2.6, 7.1 and 8.1 μM against H357, SCC4 and SCC9 cells, respectively. And the normal HOK cell line did not show any cell death effect. Cell Proliferation Assay [4] Cell Line: H357 Concentration: 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time: 0, 8 and 16 h Result: Inhibited the proliferation. Western Blot Analysis [4] Cell Line: H357 Concentration: 1, 2.5 and 5 μM Incubation Time: 48 h Result: Significantly reduced DDX3 protein expression levels, but not completely ablated as compared to DMSO treated cells. Up regulated the expression of E-cadherin. Apoptosis Analysis [4] Cell Line: H357 Concentration: 2.5 and 5 μM Incubation Time: 48 h Result: Induced apoptosis.

体内活性

Ketorolac (RS37619) (0.4% ketorolac tromethamine ophthalmic solution) shows powerful ocular anti-inflammatory activities in rabbits [1]. Ketorolac (4 mg/kg/day, p.o.; 2 weeks) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats [2]. Ketorolac (60 μg; intrathecal injection; once) attenuates the damage caused by spinal cord ischemia in rats [3]. Ketorolac salt (20 and 30 mg/kg; i.p.; two times in a week for 3 weeks) reduces oral carcinogenesis in mice [4]. Animal Model: New Zealand White rabbits (2.0–2.7 kg), LPS endotoxin-induced ocular inflammation [1] Dosage: 50 μL ketorolac tromethamine ophthalmic solution 0.4% Administration: In eyes, twice, 2 hours and 1 hour before LPS challenge Result: Resulted in a nearly complete inhibition (98.7%) of LPS endotoxin-induced increases in FITC (fluorescein isothiocyanate)-dextran in the anterior chamber, and resulted in a nearly complete inhibition (97.5%) of LPS endotoxin-induced increases in aqueous PGE 2 concentrations in the aqueous humor. Animal Model: Male Wistar rats (400–450 g), spinal cord ischemia model [3] Dosage: 30 and 60 μg Administration: Intrathecal injection, 1 h before the ischemia induction for once Result: Significantly reduced the motor disturbances and improved the survival rate at 60 μg. Animal Model: BALB/c mice, oral carcinogenesis model [4] Dosage: 20 mg/kg and 30 mg/kg Administration: IP injection, two times in a week for 3 weeks Result: Decreased tumor burden, reduced expression of DDX3 and anti-apoptotic proteins (Bcl-2 and Mcl-1).

Cas No.

167105-81-9

分子式

C15H12CaNO3+

分子量

274.31

储存和溶解度

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years